Asa Ericsson
Malmoe, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice-Insights From the AROS Database.
Journal: Diabetes, obesity & metabolism
Published: January 13, 2026
Estimating the societal cost of type 2 diabetes in Malmö, Sweden: a register-based cost analysis.
Journal: Frontiers in clinical diabetes and healthcare
Published: April 22, 2025
Effect of Pediatric Obesity Treatment on Long-Term Health.
Journal: JAMA pediatrics
Published: January 21, 2025
Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model.
Journal: Obesity (Silver Spring, Md.)
Published: April 08, 2024
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Journal: PharmacoEconomics - open
Published: December 05, 2021
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.
Journal: Diabetes, obesity & metabolism
Published: December 01, 2021
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
Journal: Diabetes, obesity & metabolism
Published: November 10, 2020
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 12, 2020
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Journal: Journal of medical economics
Published: August 05, 2020
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.
Journal: Diabetologia
Published: April 22, 2020
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Journal: Advances in therapy
Published: September 24, 2019
Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Journal: Journal of medical economics
Published: May 03, 2019
Last Updated: 09/26/2026